首页> 外文期刊>Oncology Research >PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
【24h】

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1

机译:PDGFRA和KIT突变状态及其与临床病理特征的关系,包括DOG1

获取原文
获取原文并翻译 | 示例
       

摘要

Most of the gastrointestinal stromal tumors (GISTs) have gain-of-function mutations in the KIT gene, which can be used as a prognostic marker for the biological behavior of tumors, predictive marker for the response of tyrosine kinase inhibitors, and diagnostic marker. Researchers have focused on PDGFRA mutations because of both their prognostic and predictive potential and DOG1 positivity for diagnosis on GISTs. The aim of this study is to investigate the effect DOG1, PDGFRA, and KIT mutations on the prediction of the outcome for GIST management. Polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17 and PDGFRA gene exons 12 and 18 with the genomic DNA of 46 GIST patients, and amplicons were sequenced in both directions. Immunocytochemical stainings were done by using primary antibodies. Molecular analysis revealed that the KIT mutation was observed in 63% of all cases, while the PDGFRA mutation was observed in 23.9% of cases. Significant relationships were found between age and KIT mutation, tumor location and KIT mutations, and tumor location and PDGFRA mutations (p <= 0.05). DOG1 positivity was detected in 65.2% of all GISTs and DOG1-positive cells had a higher KIT mutation ratio than DOG1-negative cells (p <= 0.05). KIT gene exon 11 mutations in DOG1-positive cells was higher than DOG1-negative cells (p <= 0.05). Conversely, KIT gene exon 13 mutations were higher in DOG1-negative cells than DOG1-positive cells (p <= 0.05). In this study, KIT mutation frequency was found similar with the European population; conversely, PDGFRA mutation frequency was similar with an Asian-Chinese-based study. KIT/PDGFRA mutations and tumor location can be used for the prediction of tumor behavior and the management of disease in GISTs. DOG1 positivity might be a candidate marker to support KIT and PDGFRA mutations, due to the higher DOG1 positivity in KIT exon 11 mutant and stomach-and small intestine-localized GISTs.
机译:大多数胃肠道间质瘤(GIST)在KIT基因中具有功能获得性突变,可以用作肿瘤生物学行为的预后标志物,酪氨酸激酶抑制剂反应的预测标志物和诊断标志物。由于PDGFRA突变的预后和预测潜力以及对GIST的诊断的DOG1阳性,因此研究人员一直专注于PDGFRA突变。这项研究的目的是调查DOG1,PDGFRA和KIT突变对GIST管理结果预测的影响。用46名GIST患者的基因组DNA对KIT基因外显子9、11、13和17以及PDGFRA基因外显子12和18进行了聚合酶链反应,并在两个方向上进行了扩增子测序。免疫细胞化学染色是通过使用一抗进行的。分子分析表明,在所有病例中观察到KIT突变的占63%,而在23.9%病例中观察到PDGFRA突变。在年龄和KIT突变,肿瘤位置和KIT突变以及肿瘤位置和PDGFRA突变之间发现了显着的相关性(p <= 0.05)。在所有GIST中有65.2%检测到DOG1阳性,并且DOG1阳性细胞的KIT突变率高于DOG1阴性细胞(p <= 0.05)。 DOG1阳性细胞中KIT基因外显子11突变高于DOG1阴性细胞(p <= 0.05)。相反,DOG1阴性细胞中的KIT基因外显子13突变高于DOG1阳性细胞(p <= 0.05)。在这项研究中,发现KIT突变频率与欧洲人群相似。相反,PDGFRA突变频率与一项基于亚裔华裔的研究相似。 KIT / PDGFRA突变和肿瘤位置可用于预测GIST中的肿瘤行为和疾病管理。 DOG1阳性可能是支持KIT和PDGFRA突变的候选标记,因为在KIT外显子11突变体以及胃和小肠定位的GIST中DOG1阳性较高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号